Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas
- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs
Zai Lab's new cancer medicine just got special FDA recognition, which means the government thinks it could help patients with a rare, serious disease that doesn't have many treatment choices right now. This kind of approval is encouraging because it shows doctors and scientists believe the medicine might work, though we don't know for sure yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.